Titan Pharmaceuticals Inc. [TTNP] stock is down -2.90 while the S&P 500 has risen 0.01% on Tuesday, 12/01/20. While at the time of this article, TTNP ATR is sitting at 1.08, with the beta value at 1.18. This stock’s volatility for the past week remained at 24.45%, while it was 20.04% for the past 30-day period. TTNP has fallen -$0.11 from the previous closing price of $3.76 on volume of 1.02 million shares.
On 30, November 2020, Titan Pharmaceuticals Announces Reverse Stock Split. According to news published on Yahoo Finance, Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company’s common stock, which will be effective at 5:00 p.m. Eastern Time on Monday, November 30, 2020. The Company’s stockholders approved the reverse stock split at a Special Meeting of Stockholders on November 30, 2020. The Company’s shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing upon market open on December 1, 2020.
Analyst Birdseye View:
The most recent analyst activity for Titan Pharmaceuticals Inc. [NASDAQ:TTNP] stock was on November 10, 2017, when it was Downgrade with a Neutral rating from ROTH Capital. Before that, on June 26, 2019, Maxim Group Recapitulated a Buy rating and elevated its amount target to $4.
In the past 52 weeks of trading, this stock has oscillated between a low of $2.82 and a peak of $16.35. Right now, the middling Wall Street analyst 12-month amount mark is $24.00. At the most recent market close, shares of Titan Pharmaceuticals Inc. [NASDAQ:TTNP] were valued at $3.65.
Titan Pharmaceuticals Inc. [NASDAQ:TTNP] most recently reported quarterly sales of 1.12 billion, which represented growth of 22.20%. This publicly-traded organization’s revenue is $171,952 per employee, while its income is -$783,714 per employee. This company’s Gross Margin is currently 67.30%, its Pretax Margin is -455.77, and its Net Margin is -455.77. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -139.37, -398.31, -197.94 and -202.93 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 75.60 and the whole liability to whole assets at 46.64. It shows enduring liability to the whole principal at 70.97 and enduring liability to assets at 0.44 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.49 points at 1st support level, the second support level is making up to 3.23. But as of 1st resistance point, this stock is sitting at 4.16 and at 4.57 for 2nd resistance point.
Titan Pharmaceuticals Inc. [TTNP] reported its earnings at -$1.5 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$1.05/share signifying the difference of -0.45 and -42.90% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$1.5 calling estimates for -$1.05/share with the difference of -0.45 depicting the surprise of -42.90%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Titan Pharmaceuticals Inc. [NASDAQ:TTNP] is 1.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.45. Now if looking for a valuation of this stock’s amount to sales ratio it’s 1.23 and it’s amount to book ratio is 7.77.